Avanir Pharmaceuticals has completed targeted enrolment of patients into the STAR trial, a confirmatory phase-III trial of Zenvia (dextromethorphan/quinidine [DM/Q]) in patients exhibiting signs and symptoms of pseudobulbar affect (PBA). The randomized, multi-centre, international STAR trial is designed to compare the effects of Zenvia 30/10 mg, Zenvia 20/10 mg and placebo on involuntary crying/laughing episodes rates.

 Vision and Boldness Are Needed to Execute a Winning Strategy in the Near Future -

The U.S.-based pharmaceutical industry received a sliver of good news last year when first-of-a-kind drug approvals in the U.S. reached a three-year high. Twenty-four drugs were approved during 2008, compared to only 18 in 2007.

Cyclogenix Ltd announced that it has entered into license and research agreements with Wyeth Pharmaceuticals, a division of Wyeth and IMBcom, The University of Queensland's (UQ) company for commercializing technology from the Institute for Molecular Bioscience (IMB).

Waters XenoTech has begun offering new metabolite profiling services. This has been possible with the Synapt High Definition Mass Spectrometry (HDMS) System.